This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy. It is designed for patients with stage II-IIIA non-small cell lung cancer. The efficacy and safety of hypofractionated radiotherapy sequential tislelizumab and anlotinib in the neoadjuvant and adjuvant treatment of stage II-IIIA non-small cell lung cancer are observed. Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.
(1) Aged 18-75 years old;
(2) Early stage II-IIIA NSCLC (AJCC 8th edition), NSCLC, confirmed in tissue (AJCC eighth edition);
(3) All lesions are assessed to be eligible for surgical resection;
(4) The primary tumor can be treated with hypofractionated radiotherapy after evaluation;
(1) The location of the primary tumor was assessed by the radiologist and considered unsuitable for hypofractionated therapy;
(2) The pathological type is small cell lung cancer, or mixed tumor with small cell components;
(3) A history of or concurrent with other malignancies;
(4) Received any anti-tumor treatment before this study, including chemotherapy, radiotherapy, targeted therapy (including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitors, etc.) and immunotherapy;
Ji Yongling
Lead sponsor
Zhejiang Cancer Hospital
Sponsor institution